Any current/future capex/capital investment/strategic investment?

No explicit current capital expenditure or strategic investment details were disclosed in the call. The company is actively pursuing 2-3 acquisition targets, focusing on emerging markets and established brand businesses to supplement portfolio growth. Rajeev Nannapaneni mentioned a preference for acquisitions outside India due to better returns despite currency and political risks. They currently have enough cash (approx. INR2,500 crores net) post Adcock acquisition and prefer preserving cash for large acquisitions rather than buybacks. Financing for large acquisitions may be a mix of cash, de

Future growth expectations in sales/revenue/volumes?

Anticipated revenue for fiscal 2026 is around INR 4,300 crores, based on Q3 and Q4 projections (Page 12). Emerging markets (Middle East, Brazil) and Adcock profit consolidation expected to drive growth in export revenue (Page 17). Domestic Indian market expected to grow over 20% in the next year, driven primarily by semaglutide (Page 12). U.S. market: Several ANDA approvals and product launches, including first-to-file/shared first-to-file, expected in the next 12 months, contributing to growth (Page 16). Base business expected to stabilize in H2 FY26; new product launches will increme

Future growth expectations in earnings/operating earnings/profits/EPS?

For fiscal year 2026, Natco expects revenue around INR 4,300 crores and PAT between INR 1,280-1,300 crores (Page 12). Emerging markets, including Brazil and Middle East, along with Adcock profit consolidation, are anticipated to drive future growth (Page 17). The U.S. market is expected to see strong launches supporting growth in fiscal 2027 (Page 17). Domestic growth in India is projected to exceed 20% mainly driven by semaglutide (Page 12). The company maintains confidence in comfortable growth over the next couple of years, with detailed guidance expected in the May call after audited numbe

IN US

Sale is live|00:00:00left today

Natco Pharma LtdQ4 FY27Pharmaceuticals & Biotechnology

Natco Pharma Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹904P/E: 13.8Market Cap: ₹21.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Anticipated revenue for fiscal 2026 is around INR 4,300 crores, based on Q3 and Q4 projections (Page 12).
→Emerging markets (Middle East, Brazil) and Adcock profit consolidation expected to drive growth in export revenue (Page 17).
→Domestic Indian market expected to grow over 20% in the next year, driven primarily by semaglutide (Page 12).
→U.S. market: Several ANDA approvals and product launches, including first-to-file/shared first-to-file, expected in the next 12 months, contributing to growth (Page 16).
→Base business expected to stabilize in H2 FY26; new product launches will increment growth (Page 16).
→Management confident of comfortable growth over next couple of years (Page 17).
→Long-term aspiration to reach ~INR 10,000 crores turnover, largely through M&A and geographic expansion (Page 10).

Margin guidance

Category 3

→For fiscal year 2026, Natco expects revenue around INR 4,300 crores and PAT between INR 1,280-1,300 crores (Page 12).
→Emerging markets, including Brazil and Middle East, along with Adcock profit consolidation, are anticipated to drive future growth (Page 17).
→The U.S. market is expected to see strong launches supporting growth in fiscal 2027 (Page 17).
→Domestic growth in India is projected to exceed 20% mainly driven by semaglutide (Page 12).
→The company maintains confidence in comfortable growth over the next couple of years, with detailed guidance expected in the May call after audited numbers (Page 17).
→R&D expenditure remains prioritized for complex generics, supporting future pipeline-driven growth (Page 6).
→M&A activity, especially outside India, is targeted to supplement organic growth and accelerate scale (Page 10, 17-18).

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

- Currently, Natco Pharma does not plan to raise any capital through debt or equity as they have sufficient cash reserves. - The management is not a big fan of debt but will make judgment calls closer to the time if acquisition opportunities arise. - For large acquisitions, the company may consider a mix of cash, debt, and equity financing. - Presently, no capital raising is planned, but if a large transaction occurs, Natco Pharma is open to changing this stance. - The focus is on preserving cash for potential large acquisitions similar to Adcock Ingram. - Actively pursuing 2-3 acquisition targets with hopes to close at least 1 or 2 deals in 2025 or 2026, subject to clearances. (Source: Page 10 and Page 11 of the transcript)

Order book

The transcript does not provide explicit details on the current or expected order book/pending orders. However, key related points include: - The company expects strong growth in the U.S. market with several ANDA approvals and product launches expected in the next 12 months, including a shared First-to-File (FTF) launch. - Emerging markets like Brazil and Middle East are showing good product launches and approvals, expected to drive export revenue growth. - Domestic market growth is largely driven by semaglutide, with a 20%+ growth target in India. - Multiple Para IV litigations and patent challenges are ongoing, impacting timelines for specific product launches. - The company is actively pursuing 2-3 large M&A targets to supplement its portfolio and geographical expansion. - R&D filings include 4-5 products this year, with 8 expected in total. No explicit order book size or pending order value was shared during the call.

Capex plans

Yes

→No explicit current capital expenditure or strategic investment details were disclosed in the call.
→The company is actively pursuing 2-3 acquisition targets, focusing on emerging markets and established brand businesses to supplement portfolio growth.
→Rajeev Nannapaneni mentioned a preference for acquisitions outside India due to better returns despite currency and political risks.
→They currently have enough cash (approx. INR2,500 crores net) post Adcock acquisition and prefer preserving cash for large acquisitions rather than buybacks.
→Financing for large acquisitions may be a mix of cash, debt, and equity depending on the size and circumstances.
→There is no plan to raise capital immediately, but fundraising could be considered if a large acquisition opportunity arises.
→No specific capex plans for manufacturing were detailed; FDA plant statuses were updated but no fresh investments mentioned.

How does Natco Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Natco Pharma Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Natco Pharma Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio